164 related articles for article (PubMed ID: 26406003)
1. Identification of dual active agents targeting 5-HT1A and SERT by combinatorial virtual screening methods.
Wang P; Yang F; Yang H; Xu X; Liu D; Xue W; Zhu F
Biomed Mater Eng; 2015; 26 Suppl 1():S2233-9. PubMed ID: 26406003
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial support vector machines approach for virtual screening of selective multi-target serotonin reuptake inhibitors from large compound libraries.
Shi Z; Ma XH; Qin C; Jia J; Jiang YY; Tan CY; Chen YZ
J Mol Graph Model; 2012 Feb; 32():49-66. PubMed ID: 22064367
[TBL] [Abstract][Full Text] [Related]
3. QSAR Analysis of Multimodal Antidepressants Vortioxetine Analogs Using Physicochemical Descriptors and MLR Modeling.
Rajathei DM; Parthasarathy S; Selvaraj S
Curr Comput Aided Drug Des; 2019; 15(4):294-307. PubMed ID: 30317998
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output.
van Amsterdam C; Seyfried CA
Psychopharmacology (Berl); 2014 Jun; 231(12):2547-58. PubMed ID: 24419272
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like activity of YL-0919: a novel combined selective serotonin reuptake inhibitor and 5-HT1A receptor agonist.
Chen HX; Jin ZL; Zhang LM; Xue R; Xu XD; Zhao N; Qiu ZK; Wang XW; Zhang YZ; Yang RF; Li YF
PLoS One; 2013; 8(12):e83271. PubMed ID: 24367588
[TBL] [Abstract][Full Text] [Related]
6. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
7. Discovery of DSP-1053, a novel benzylpiperidine derivative with potent serotonin transporter inhibitory activity and partial 5-HT
Yoshinaga H; Nishida T; Sasaki I; Kato T; Oki H; Yabuuchi K; Toyoda T
Bioorg Med Chem; 2018 May; 26(8):1614-1627. PubMed ID: 29456112
[TBL] [Abstract][Full Text] [Related]
8. The role of activation of the 5-HT1A receptor and adenylate cyclase in the antidepressant-like effect of YL-0919, a dual 5-HT1A agonist and selective serotonin reuptake inhibitor.
Qin JJ; Chen HX; Zhao N; Yuan L; Zhang YZ; Yang RF; Zhang LM; Li YF
Neurosci Lett; 2014 Oct; 582():104-8. PubMed ID: 25220701
[TBL] [Abstract][Full Text] [Related]
9. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT
Zheng G; Xue W; Yang F; Zhang Y; Chen Y; Yao X; Zhu F
Phys Chem Chem Phys; 2017 Nov; 19(42):28885-28896. PubMed ID: 29057413
[TBL] [Abstract][Full Text] [Related]
10. Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT
Walory J; Mielczarek L; Jarończyk M; Koronkiewicz M; Kossakowski J; Bugno R; Bojarski AJ; Chilmonczyk Z
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30347827
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor.
Stahl SM
CNS Spectr; 2014 Apr; 19(2):105-9. PubMed ID: 24673885
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder.
Bang-Andersen B; Ruhland T; Jørgensen M; Smith G; Frederiksen K; Jensen KG; Zhong H; Nielsen SM; Hogg S; Mørk A; Stensbøl TB
J Med Chem; 2011 May; 54(9):3206-21. PubMed ID: 21486038
[TBL] [Abstract][Full Text] [Related]
13. Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders.
Dawson LA; Watson JM
CNS Neurosci Ther; 2009; 15(2):107-17. PubMed ID: 19499624
[TBL] [Abstract][Full Text] [Related]
14. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. part 3.
Herold F; Chodkowski A; Izbicki Ł; Turło J; Dawidowski M; Kleps J; Nowak G; Stachowicz K; Dybała M; Siwek A; Mazurek AP; Mazurek A; Pluciński F
Eur J Med Chem; 2011 Jan; 46(1):142-9. PubMed ID: 21093118
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, antidepressant evaluation and docking studies of long-chain alkylnitroquipazines as serotonin transporter inhibitors.
Gabrielsen M; Wołosewicz K; Zawadzka A; Kossakowski J; Nowak G; Wolak M; Stachowicz K; Siwek A; Ravna AW; Kufareva I; Kozerski L; Bednarek E; Sitkowski J; Bocian W; Abagyan R; Bojarski AJ; Sylte I; Chilmonczyk Z
Chem Biol Drug Des; 2013 Jun; 81(6):695-706. PubMed ID: 23574807
[TBL] [Abstract][Full Text] [Related]
16. Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research.
Celada P; Bortolozzi A; Artigas F
CNS Drugs; 2013 Sep; 27(9):703-16. PubMed ID: 23757185
[TBL] [Abstract][Full Text] [Related]
17. Discovery of SMP-304, a novel benzylpiperidine derivative with serotonin transporter inhibitory activity and 5-HT
Yoshinaga H; Masumoto S; Koyama K; Kinomura N; Matsumoto Y; Kato T; Baba S; Matsumoto K; Horisawa T; Oki H; Yabuuchi K; Kodo T
Bioorg Med Chem; 2017 Jan; 25(1):293-304. PubMed ID: 27865645
[TBL] [Abstract][Full Text] [Related]
18. Vilazodone does not inhibit sexual behavior in male rats in contrast to paroxetine: A role for 5-HT1A receptors?
Oosting RS; Chan JSW; Olivier B; Banerjee P
Neuropharmacology; 2016 Aug; 107():271-277. PubMed ID: 27040795
[TBL] [Abstract][Full Text] [Related]
19. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
20. Neurochemical and behavioural effects of hypidone hydrochloride (YL-0919): a novel combined selective 5-HT reuptake inhibitor and partial 5-HT
Zhang LM; Wang XY; Zhao N; Wang YL; Hu XX; Ran YH; Liu YQ; Zhang YZ; Yang RF; Li YF
Br J Pharmacol; 2017 May; 174(9):769-780. PubMed ID: 27882537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
